NCT04621409 is a EARLY_PHASE1 clinical trial of Liver-enriched antimicrobial peptide 2 in Obesity, sponsored by University Hospital, Gentofte, Copenhagen.

Who is sponsoring NCT04621409?

NCT04621409 is sponsored by University Hospital, Gentofte, Copenhagen.

What drugs are being tested in NCT04621409?

Interventions in NCT04621409: Liver-enriched antimicrobial peptide 2, Placebo.

Is NCT04621409 still recruiting?

NCT04621409 is currently completed. Last updated 26 May 2021.

Last reviewed 2021-05-26 · How we verify

NCT04621409

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LEAP2 on Postprandial Glucose Metabolism and Food Intake

Completed EARLY_PHASE1 Last updated 26 May 2021

What this trial tests

EARLY_PHASE1 trial testing Liver-enriched antimicrobial peptide 2 in Obesity in 20 participants. Completed in 18 February 2021.

Timeline

17 November 2020

Primary endpoint
18 February 2021

18 February 2021

Quick facts

Lead sponsor	University Hospital, Gentofte, Copenhagen
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	20
Start date	17 November 2020
Primary completion	18 February 2021
Estimated completion	18 February 2021
Sites	1 location across Denmark

Drugs / interventions tested

Liver-enriched antimicrobial peptide 2 — full drug profile →
Placebo

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

University Hospital, Gentofte, Copenhagen

Who can join

Adults 18 to 25, male only, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aim to delineate the effects of the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2) on postprandial glucose metabolism and food intake in healthy volunteers. The overall objective is to investigate the physiological importance of LEAP-2 in healthy subjects.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

LEAP2 reduces postprandial glucose excursions and <i>ad libitum</i> food intake in healthy men.
Hagemann CA, Jensen MS, Holm S, Gasbjerg LS, et al · · 2022 · cited 52× · PMID 35492241 · DOI 10.1016/j.xcrm.2022.100582
57<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes.
· 2021 · cited 11× · PMID 34468792 · DOI 10.1007/s00125-021-05519-y
Progress in the classification, optimization, activity, and application of antimicrobial peptides.
Su Z, Yu H, Lv T, Chen Q, et al · · 2025 · cited 9× · PMID 40336834 · DOI 10.3389/fmicb.2025.1582863
Targeting the Gut in Obesity: Signals from the Inner Surface.
Petersen N, Greiner TU, Torz L, Bookout A, et al · · 2022 · cited 5× · PMID 35050161 · DOI 10.3390/metabo12010039
Protocol for assessing the effects of exogenous hormone administration on human postprandial glucose metabolism, appetite sensations, and food intake.
Hagemann CA, Gasbjerg LS, Christensen MB, Knop FK. · · 2023 · cited 1× · PMID 36853704 · DOI 10.1016/j.xpro.2023.102070

Verify or expand the search:

Other trials of Liver-enriched antimicrobial peptide 2

Trials testing the same drug.

NCT04897984 — LEAP2 Kinetics in Healthy Individuals · EARLY_PHASE1 · completed
NCT04043065 — Liver-enriched Antimicrobial Peptide 2 · EARLY_PHASE1 · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other University Hospital, Gentofte, Copenhagen trials

Trials by the same sponsor.

NCT07171723 — Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment · Phase 1, PHASE2 · recruiting
NCT06934473 — Effects of Endogenous GIP on Postprandial Blood Pressure in Healthy Individuals · NA · recruiting
NCT06845033 — Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity · NA · not yet recruiting
NCT06787001 — Understanding How Gut and Brain Barriers Are Linked to Inflammation in Obesity · completed
NCT06881459 — The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients With Type 1 Diabetes · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04621409 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Gentofte, Copenhagen
Last refreshed: 26 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04621409.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing